<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Delphine Kemlin</style></author><author><style face="normal" font="default" size="100%">Nicolas Gemander</style></author><author><style face="normal" font="default" size="100%">Stéphanie Depickère</style></author><author><style face="normal" font="default" size="100%">Véronique Olislagers</style></author><author><style face="normal" font="default" size="100%">Daphnée Georges</style></author><author><style face="normal" font="default" size="100%">Alexandra Waegemans</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Anne Lemy</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Johan Michiels</style></author><author><style face="normal" font="default" size="100%">Marylène Vandevenne</style></author><author><style face="normal" font="default" size="100%">Heyndrickx, Leo</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author><author><style face="normal" font="default" size="100%">André Matagne</style></author><author><style face="normal" font="default" size="100%">Margaret E. Ackerman</style></author><author><style face="normal" font="default" size="100%">Le Moine, Alain</style></author><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Transplant</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibodies, Neutralizing</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">Breakthrough Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-gamma</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplant Recipients</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 May</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;As solid organ transplant recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received 3 doses of BNT162b2 mRNA vaccine. Associations among breakthrough infection (BTI), vaccine responses, and patient characteristics were explored in 54 patients. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of 6 months after booster vaccination. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate Analyses identified the avidity of SARS-CoV-2 receptor binding domain binding IgG, neutralizing antibodies, and SARS-CoV-2 S2-specific interferon gamma responses as correlates of protection against BTI. No demographic or clinical parameter correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific interferon gamma responses. In conclusion, T cell responses may help compensate for the suboptimal antibody response to booster vaccination in kidney transplant recipients. Further studies are needed to confirm these findings.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record></records></xml>